Bone Marrow Neuroblastoma Metastases in the Liver and and Complete Regression of Disseminated Sensitization , Tumor-Specific CTL Reactivity IL-27 and IL-2 : Enhancement of T Cell Immunologic and Therapeutic Synergy of and

[1]  M. Huber,et al.  IL-27 inhibits the development of regulatory T cells via STAT3. , 2008, International immunology.

[2]  I. McInnes,et al.  Interleukin 27 attenuates collagen-induced arthritis , 2008, Annals of the rheumatic diseases.

[3]  M. Neurath,et al.  IL‐27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1 , 2007, European journal of immunology.

[4]  A. Chang,et al.  Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment1 , 2007, The Journal of Immunology.

[5]  L. Hennighausen,et al.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. , 2007, Immunity.

[6]  Bryon D Johnson,et al.  CD25+ Regulatory T Cell Inhibition Enhances Vaccine-induced Immunity to Neuroblastoma , 2007, Journal of immunotherapy.

[7]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[8]  T. Yoshimoto,et al.  Augmentation of Effector CD8+ T Cell Generation with Enhanced Granzyme B Expression by IL-27 1 , 2005, The Journal of Immunology.

[9]  John M Maris,et al.  The biologic basis for neuroblastoma heterogeneity and risk stratification , 2005, Current opinion in pediatrics.

[10]  R. Kastelein,et al.  IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells1 , 2004, The Journal of Immunology.

[11]  R. de Waal Malefyt,et al.  IL‐12 and IL‐23: master regulators of innate and adaptive immunity , 2004, Immunological reviews.

[12]  M. Tagawa,et al.  Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells. , 2004, Anticancer research.

[13]  T. Malek,et al.  Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.

[14]  Maria Laura Belladonna,et al.  Potent Antitumor Activity of Interleukin-27 , 2004, Cancer Research.

[15]  G. Trinchieri,et al.  The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. , 2003, Immunity.

[16]  R. Kastelein,et al.  IL-27 and IFN-α Signal via Stat1 and Stat3 and Induce T-Bet and IL-12Rβ2 in Naive T Cells , 2003 .

[17]  Hiroshi Yamamoto,et al.  Induction of systemic immunity by expression of interleukin‐23 in murine colon carcinoma cells , 2003, International journal of cancer.

[18]  Cheng-Wen Wu,et al.  Antitumor and Antimetastatic Activity of IL-231 , 2003, The Journal of Immunology.

[19]  S. Hart,et al.  Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12 , 2003, British Journal of Cancer.

[20]  M. Lotze,et al.  Combined Treatment With Interleukin-18 and Low-Dose Interleukin-2 Induced Regression of a Murine Sarcoma and Memory Response , 2003, Journal of immunotherapy.

[21]  M. Lotze,et al.  Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. , 2003, Journal of pediatric surgery.

[22]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[23]  Simon C Watkins,et al.  Cellular mechanisms of interleukin-12-mediated neuroblastoma regression. , 2003, Journal of pediatric surgery.

[24]  A. Gurney,et al.  Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17* , 2003, The Journal of Biological Chemistry.

[25]  T. Nagai,et al.  Interferon-β differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells , 2002, Journal of Neuroimmunology.

[26]  W. Alvord,et al.  Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN-γ and Fas-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-21 , 2002, The Journal of Immunology.

[27]  D. Robinson,et al.  Further checkpoints in Th1 development. , 2002, Immunity.

[28]  T. Mcclanahan,et al.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. , 2002, Immunity.

[29]  S. Swain,et al.  Interleukin 18 , 2001, The Journal of experimental medicine.

[30]  Simon C Watkins,et al.  Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma , 2001 .

[31]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[32]  A. Nagler,et al.  AMPLIFICATION OF IMMUNOLOGICAL FUNCTIONS BY SUBCUTANEOUS INJECTION OF INTERMEDIATE-HIGH DOSE INTERLEUKIN-2 FOR 2 YEARS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN CHILDREN WITH STAGE IV NEUROBLASTOMA , 2000, Transplantation.

[33]  H Bönig,et al.  In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors , 2000, Bone Marrow Transplantation.

[34]  J Pritchard,et al.  Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. , 2000, European journal of cancer.

[35]  A. Davidoff,et al.  Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12. , 1999, Journal of pediatric surgery.

[36]  G. Vassal,et al.  Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution , 1999, Bone Marrow Transplantation.

[37]  G. Trinchieri,et al.  Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. , 1998, The Journal of clinical investigation.

[38]  H. Okamura,et al.  References Subscriptions Permissions Email Alerts IFN-γ-Inducing Factor/IL-18 Administration Mediates IFN- γ- and IL-12-Independent Antitumor Effects , 2013 .

[39]  K. Matthay,et al.  A Phase I/IB trial of murine monoclonal anti‐GD2 antibody 14.G2a plus interleukin‐2 in children with refractory neuroblastoma , 1997, Cancer.

[40]  T. Tanimoto,et al.  In vivo antitumor effects of murine interferon- γ -inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites , 1997, Cancer Immunology, Immunotherapy.

[41]  T. Philip,et al.  Autologous stem cell transplantation for solid tumors in children , 1997, Current opinion in pediatrics.

[42]  J. Franco,et al.  Evaluation of the Antitumor Activity of the Interleukin‐12/Pulse Interleukin‐2 Combination a , 1996, Annals of the New York Academy of Sciences.

[43]  G. Vassal,et al.  Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. , 1996, Bone marrow transplantation.

[44]  J. Franco,et al.  Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. , 1996, Journal of the National Cancer Institute.

[45]  Kendall A. Smith,et al.  Interleukin‐2 Deficient Mice: A New Model to Study Autoimmunity and Self‐Tolerance , 1995, Immunological reviews.

[46]  H. Fujiwara,et al.  Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. , 1995, International immunology.

[47]  G. Reaman,et al.  A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study , 1995, Cancer.

[48]  M. Lotze,et al.  Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. , 1995, Journal of Surgical Research.

[49]  R. Seeger,et al.  Treatment of Neuroblastoma Patients with Antiganglioside GD2 Antibody plus Interleukin‐2 Induces Antibody‐Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[50]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[51]  L. Neckers,et al.  A Phase I Study of Interleukin‐2 in Children with Cancer , 1992, The American journal of pediatric hematology/oncology.

[52]  G. Pavlakis,et al.  Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein , 1992, Journal of virology.

[53]  F. Podlaski,et al.  Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Favrot,et al.  A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases. , 1989, Cancer treatment reviews.

[55]  A. Yoshimura,et al.  STAT 3-Dependent Mechanism T Cells Partially Through + Activated CD 4 Production Including IL-23-Induced IL-17 on Suppression of Proinflammatory Cytokine T Cells versus + Differentiation on Naive CD 4 Two-Sided Roles of IL-27 : Induction of Th 1 , 2006 .

[56]  千代 雅子.  Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals , 2005 .

[57]  S. Cohn,et al.  Advances in the diagnosis and treatment of neuroblastoma. , 2003, The oncologist.

[58]  C. R. Pinkerton,et al.  Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. , 2001, Medical and pediatric oncology.

[59]  S. Gillies,et al.  Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. , 1998, Blood.

[60]  J. Hank,et al.  Combination therapy with interleukin-2 and antitumor monoclonal antibodies. , 1997, The cancer journal from Scientific American.

[61]  J. Wigginton,et al.  Antitumor activity of interleukin 12 in preclinical models , 1996, Cancer Chemotherapy and Pharmacology.

[62]  S. Burchill,et al.  Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. , 1995, European journal of cancer.